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Retinoic acid receptor a mediates growth inhibition by
retinoids in rat pancreatic carcinoma DSL-6A/CI cells
FH Brembeckl, A Kaiser', K Detjen1, H Hotz2, T Foitzik2, HJ Buhr2, E-O Riecken1 and S Rosewiczl
Department of Gastroenterology. Medizinische Klinik 1. 2Department of Surgery. Klinikum Benjamin Franklin. FU Berlin/Germany. Hindenburgdamm 30.
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Summary During carcinogenesis. pancreatic acinar cells can dedifferentiate into ductal adenocarcinoma of the pancreas. DSL-6AIC1 cells
represent an in vitro model of this carcinogenic sequence. This study was designed to examine the effects of retinoids on cell growth in DSL-
6A/C1 cells and to characterize further the molecular mechanisms underlying the antiproliferative actions of retinoids. Treatment of DSL-
6A/C1 cells with retinoids results in a time- and dose-dependent inhibition of cell growth, paralleled by a retinoid-mediated transactivation of
a pTK::]RAREx2-luciferase reporter construct transientty transfected into DSL-6A/C1 cells. Retinoid receptor expression was evaluated by
reverse transcriptase polymerase chain reaction (RT-PCR) using subtype-specific primers and demonstrated expression of retinoic acid
receptor alpha (RAR-a), RAR-I and retinoid X receptor alpha (RXR-a). Using a panel of receptor subtype-specific agonists, the RAR-a
specific agonist Ro 40-6055 was the most potent retinoid in terms of growth inhibition. Furthermore, all-trans-retinoic acid-mediated growth
inhibition and transactivation was completely blocked by the RAR-a-speciflc antagonist Ro 41-5253. In summary, the RAR-a subtype
predominantly mediates the antiproliferative effects of retinoids in DSL-6AJC1 cells. Furthermore, this cell system provides a feasible tool to
study the molecular mechanisms underlying the growth inhibitory effects of retinoids in ductal pancreatic carcinoma cells derived from a
primary acinar cell phenotype.
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Despite intensive clinical trials durinn the last decades. therapy of
advanced human exocrine pancreatic carcinoma remains unsatis-
factory: onl1 few chemo- and radiochemotherapeutic regimen
have produced modest surxix al benefits in patients with advanced
disease (Lionetto et al. 1995). Therefore. alternative treatment
strategies have focused on substances which exert their anti-
tumorigenic effects by growth inhibition and induction of cellular
differentiation. rather than cvtotoxicitv. In this context. retinoids
have recently emerged as a novel therapeutic strategy for the treat-
ment of human pancreatic carcinoma (Rosewicz et al. 1995a:
Brembeck et al. 1998). Previous studies were performed using
cultured human ductal pancreatic carcinoma cell lines. because
more than 90% of human pancreatic cancers are histoloaicallv
classified as ductal adenocarcinoma of the exocrine pancreas.
How-ever. the pathogenesis ofpancreatic cancer remains unsolved.
especiallx regarding the cell type oforiain (acinar versus duct cell)
as the primary progenitor of the carcinogenic pathway. A
carcinogen-induced model in the Syrian golden hamster results in
primary ductal pancreatic carcinoma. harbouring a point mutation
at codon 12 of the K-ras gene. as is characteristicallv observed in
the majority of human tumours (Cerny et al. 1990): other animal
models of pancreatic carcinoma suggest that this malianancv is
probably not derived from a primarn duct cell origin because it
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could be demonstrated that acinar cells upon malignant transfor-
mation can dedifferentiate to a duct-like cell type in some rodents
(rats and mice) without aquisition ofK-ras point mutations (Dissin
et al. 1975: Longnecker and Curphey. 1975: Bockman et al. 1976.
1978: Satake et al. 1984: Scarpelli et al. 1984: De Lisle and
Logsdon. 1990: Longnecker et al. 1992: Pettengill et al. 1993). As
an in -itro model for this 'transdifferentiation' theory ofpancreatic
carcinogenesis. Pettengill et al (1993) established the DSL-6A/C1
cell line from an azaserine-induced acinar carcinoma ofthe rat and
obtained a cell line with duct cell-specific properties by regrafting
the tumour cells from in vivo to in vitro and vice versa. Althourh
not experimentally proven. it appears conceivable that this
carcinogenic sequence might also apply for human pancreatic
carcinoma aiven that more than 90% of the human exocrine
pancreas is represented by acinar cells. Therefore. the aim of our
study was to establish this cell line as a suitable in vitro model to
investigate the molecular mechanisms involved in retinoid-
mediated growth inhibition.
Retinoids. which are summarized as natural and synthetic deriv-
atiN-es of vitamin A. have been demonstrated to inhibit prolifera-
tion and induce differentiation in a variety of malignant tissues
(Lotan. 1980: Bollag. 1983: Lotan et al. 1990: Love and Gudas.
1994). Clinical trials demonstrated beneficial effects of retinoids
in the treatment of Xarious premalignant lesions and malig'nancies
(reviewed by Bollag and Holdener. 1992: Smith et al. 1992:
Tallman and Wiernik. 1992). The molecular action of retinoids
was partially elucidated within the past decade. After passive
diffusion through the cell membrane. retinoids interact wvith two
cytoplasmic retinoid-binding proteins. which are believed to reau-
late intracellular retinoid homeostasis (GIauere. 1994). Retinoids
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exert their pleiotropic effects on cell growth and differentiation via
tx%&o families of nuclear retinoid receptors: the retinoic acid recep-
tors (RAR) and the retinoid X receptors (RXR) (Umesono. 1991:
Gigu&re. 1994). Each retinoid receptor family consists of three
different subtypes (Ct. . y) encoded by distinct aenes
(Mangelsdorf et al. 1994). The RAR subtypes can further be
divided in multiple isoforms because of gene transcription via
different use of two internal promoter sites or. alternatively. by
different splicing of the mRNA transcripts (Kastner et al. 1990:
Zelent et al. 1991: Giguere. 1994). The distinct receptor subtypes
are expressed in a cell type-specific pattern during embryogenesis.
in the adult organism as well as in malignant tissues. It has there-
fore been concluded that retinoid sensitivity of a given tissue is
defined in part through the expression pattern of RARIRXR
subtypes (Gigaure. 1994).
RARs are bound and activated by the naturally occurring
retinoid all-trans-retinoic acid (Leid et al. 1992a: Gigaure. 1994).
In contrast. RXRs are predominantly activated by 9-cis-retinoic
acid (Heyman et al. 1992: Leid et al. 1992b). whereas ATRA does
not bind to these receptors (Mangelsdorf et al. 1992). Binding of9-
cis-RA is necessary to form RXR homodimers or heterodimers of
the RXRs with the RARs.
Retinoid receptors are part of the nuclear vitamin D-thvroid
hormone receptor superfamily. which act as ligand-activated tran-
scription factors of retinoid-regulated genes and gene networks
(Green and Chambon. 1988). The ligand-activated RARs and
RXRs bind as dimers to their responsive elements. the retinoic
acid responsive elements (RAREs) or retinoid X responsive
elements (RXREs) (Leid et al. 1992a. Activation or suppression
ofretinoid-reaulated genes is mainly mediated through the binding,
of RARIRXR heterodimers to a 'retinoic acid responsive element
(RARE) within the promoter reaion of such aenes (Naiir et al.
1991: Umesono et al. 1991: Durand et al. 1992: Kliewer et al.
1992). Only RARJRXR heterodimers have been shown to bind
effectively to a 'retinoic acid responsive element of retinoid-
regulated genes (Leid et al. 1992a). In addition. retinoid receptors
interact with a Xvariety of co-activators and co-repressors. thereby
either relieving repression by the basal transcription machinery or
inducing ligand-dependent transcription above the basal level
(Mangelsdorf and Chambon. 1995).
Tberefore. in a given cell or tissue. retinoid sensitivity as well as
the spectrm ofbiological effects elicited by retinoids are determined
by the expression pattern of the nuclear retinoid receptor subtypes
and by different heterodimeric RAR/RXR combinations.
Consequently. for the understanding of retinoid-mediated growth
inhibition in pancreatic carcinoma cells. it appears necessary to char-
acterize the retinoid receptor subtype expression as well as the
biological function of individual retinoid receptor subtypes. In the
present study. we therefore evaluated the molecular effects of
retinoids in the cell line DSL6A/CI as amodel for ductal pancreatic
carcinoma derived fromprimary acinarcells. Furhermore, we identi-
fied the particular receptor subtype responsible for retinoid-mediated
control ofproliferation in this pancreatic carcinoma cell line.
MATERIALS AND METHODS
Materials
The rat pancreatic carcinoma cell lines DSL-6AIC1 and AR42J
were obtained from the American Type Tissue Culture Collection
(ATCC. Rockville. USA) and the human pancreatic carcinoma cell
line Dan-G from Deutsches Krebsforschungszentrum (DKFZ.
Heidelberg. Germany): Dulbecco's modified Eagle medium
(DMEM) was obtained from Gibco BRL (Berlin. Germany) and
fetal calf serum (FCS) from Biochrom (Berlin. Germany).
[ac'P]dCTP (6000 Ci mmol-1) was purchased from DuPont (Bad
Homburg. Germany): Random priming labellin, kit and
HvbondN+ membranes were obtained from Amersham
(Braunschweig. Germany). RNA molecular size markers. random
hexamer primers. Molonev murine leukaemiavirus reverse tran-
scriptase (M-MLV). T4 polynucleotide kinase and restriction
enzymes were obtained from Bethesda Research Laboratories
(BRL. Bethesda. USA). Thermus aquaticus (Taq) DNA poly-
merase was purchased from Promega (Heidelberg. Germany). The
cDNA probes for the human RAR-t. RAR-P. RAR-y,. RXR-c.
RXR-4 and mouse RXR-y were kindly provided by P Chambon
(Strasbourg. France): the pTK::PRAREx2-luc construct was
kindly provided by R Evans (San Diego. USA): all retinoids were
kindly provided by Hofmann-LaRoche (Basle. Switzerland). All
other chemicals were of analytical grade and purchased from
Sigma (Deisenhofen. Germany).
Cell culture
Cells were grown under 95% air and 5%7 carbon dioxide at 37-C as
subconfluent monolayers in DMEM or RPMI-1640 supplemented
with either 20% v/v (AR42J) or 10% v/v (Dan-G and DSL-6A/C1)
FCS. penicillin (100U ml-') and streptomycin (100 tgc ml-'). All
experiments were carried out in the log phase ofgrowth after the
cells were seeded for 24 h. Preparation of retinoids as stock solu-
tions was performed under subdued light and aliquots were kept at
-80'C for a maximum of 4 weeks. DMSO was used as a solvent
for all retinoids. Control cells were treated with the same amount
of DMSO and the final concentration of DMSO in the culture
medium did not exceed 0.1% c (v/v) Cell viability in growth assays
was routinely checked by trypan blue staining and was routinely
found to be >95%7.
RNA isolation and Northem blot analysis
Total RNA was isolated using the RNAzol reagent (WAK Chemie
Medical. Bad Homburg. Germany) according to the instructions
of the manufacturer. Qualitative analysis of RNA was perforned
using Northem blot analysis as previously described (Rosewicz
et al. 1994). RNA was denatured in a buffer containgno 6% s/v
formaldehyde and 5% v/v formamide. subjected to electrophoretic
separation in a 1% agarose gel containing formaldehyde and then
transferred to a nylon membrane. A RNA ladder was electro-
phoresed in parallel for size determination. The cDNA probes for
synaptophysin (Rosewicz et al. 1992a). human carbonic anhydrase
II (Rosewicz et al. 1995b) and amylase (Rosewicz et al. 1989)
have been previously described. The cDNA inserts were eluted by
galasmilk with the Geneclean H kit (Dianova. Hamburg. Germany).
cDNA probes were radioactively labelled with [a 'P]dC`TP using
the random primerlabelling kitfollowing the instructions provided
by the supplier. Unincorporated nucleotides were removed by
passing the reaction sample through a Sephadex
G50 (LKB Pharmacia. Bromma. Sweden) column. The specific
activity of the probes was usually 1-2 x 109 c.p.m. pg-' DNA.
Hybridization of membranes was performed using the Quickhyb
reagaent (Stratagene. Heidelberg. Germany) according to the
manufacturer's instructions. After hybridization. membranes were
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sequentially w-ashed w-ith increasing stringency- with 2 x SSC and
I x SSC (1 x standard saline citrate = 0.15 .\ sodium chlonrde.
0.015 \t sodium citrate. pH 7.0) with 0.1% sodium dodecyl sulphate
(SDS) at room temperature. and finally with 0.1 x SSC/O.1c% SDS
at 65 C for 15 min each wash. Membranes were then exposed to






Single cell suspensions of trypsinated cells were plated in 96-well
culture dishes at a densitv of 3000 cells per well in the presence of
supplemented culture medium. After an attachment time of 12 h.
retinoids were added from stock solutions at the indicated concen-
trations. Control cells were treated with sehicle alone. At the indi-
cated time points. cells were rently washed twice with phosphate
buffered saline (PBS. Gibco BRL. Berlin. Germany) and then
harvested bv trypsinization. Viable cells were counted in a haemo-
cytometer by tr pan blue exclusion. Triplicate wells A-ere analy sed
for each data point.
Reverse transcriptase polymerase chain reaction
(RT-PCR) analysis
Reserse transcription of RINA from DSL-6A/C1 cells was
performed using 1 jgc total RNA. 100 pNM random hexamer primer.
1 nmr dithiothreitol. 6 mrrLNMg>. 500 JNiM each of dNTP. 20 U
RNAsin (Promega. Heidelberg. Germany). and murine leukaemia
Virus reserse transcriptase. This reaction mixture was promptly
used as template for the PCR at a 1:20 dilution. For amplification.
the receptor subtype specific primers complementary to human
RAR-ct. RAR-1. RAR-y. RXR-a. RXR-1 and mouse RXR-y
nucleotide sequences were exactlN used as previously described
(Roseswicz et al. 1995a). The reaction was carried out in 10 mnL
Tris-HCI buffer (pH 9.0). containing 50 mist potassium chloride.
0.01%c Triton X-100. 1 nms magnesium chloride (1.5 mM MgCl,
for RAR-CL). 200 ptm each of dNTP. 50 psi of each primer and
2.5 U Taq DNA polymerase in a final volume of50 pl. Thirty-fix-e
cycles of amplification were carried out as follows: denaturation
30 s at 92 C. annealinc 90 s at 60(C. extension 90 s at 72-C and
final extension at 72'C for 10 min. As an internal negative control.
one RNA aliquot was amplified without prior reverse transcription
to ensure that the amplified PCR product w-as not due to amplifica-








Figure 1 Expression of cell type-specific markers in pancreatic carcinoma
cells (Northem blot analysis). The expression of the ductal cell marker
carbonic anhydrase 11. the acinar cell marker amylase and synaptophysin as
a neuroendocrine-specific marker were characterized in the human ductal
pancreatic carcinoma cell line Dan-G, the rat amphicine AR42J cells and the
rat DSL-6A/C1 tumour cell line. Total RNA (30jig) was isolated and anatysed
by Northem blotting as described in Materials and methods. Ethidium
bromide stains of the gels before and after transfer to the membrane were
obtained, confirming that equal amounts of RNA for each cell line were
hybridized. Shown is a representative of three independent experiments
yielding identical results. The molecular size indicated on the right side was












Transient transfections and transactivation assays
DSL-6A/Cl cells were transiently transfected wvith the
pTK::jRAREx2-luc reporter construct. This bluescript plasmid
contains the luciferase reporter gene (Forman et al. 1995) under
the control of the herpesvirus thy'midine kinase promoter
containing two tandem copies of the retinoic acid responsive
element (RARE) ofthe human RAR-4 promoter which is followed
by the SV40 polvadenylation sicnal. For transient transfection of
DSL-6AIC1 cells. 300 000 cells were plated in six-well culture
dishes. After an attachment period of 12 h. cells were incubated
w-ith 1 ml of the transfection mixture. This mixture contained
10 g plasmid DNA and 100 dl Lipofectamine reagents (Gibco
BRL. Eggenstein. Germany) in a total xolume of 18 ml serum-free
DMEM medium. Cells were incubated for 6 h. follow-edby change
of the culture medium w-ith DMEM containing 10%7 FCS and the








Figure 2 Time-dependent effects of all-trans-retinoic acid on cell growth in
DSL-6A/C1 cells. Proliferation of DSL-6A1C1 cells after stimulation with 10 gm
ATRA was determined by cell counts in an anchorage-dependent growth
assay over a period of 4 days. Means (+s.e.m.) of absolute cell number of
triplicates in three independent experiments are indicated for vehice-treated
control cells and ATRA-stimulated cells. *Significant differences at the
P< 0.05 leve
Awith the same reporter plasmid Aere incubated w-ith vehicle alone.
Twento-four hours later. cell lxsates were obtained and luciferase
activitx of l sates was determined using the luciferase reagent
(Promega. Heidelberg. Germany) by measurement of relative
luciferase units' (RLU) in a luminometer. Results are expressed as
x-fold induction over basal acti-itv of vehicle treated controls.
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Figure 3 Dose-dependent effects of all-trans-retinoic acid on cell growth (A) and transactivation of a RARE reporter construct (B). (A) Anchorage-dependent
growth assay: DSL-6A/C1 cells were incubated with the indicated concentrations of ATRA over 96 h. Cell counts were determined and expressed as per cent of
vehicle-treated control cells. Shown are the means (± s.e.m.) of three independent experiments, each performed in triplicates. *P-values <0.05 vs control.
(B) Transactivation assays: DSL-6A/C1 cells were transiently transfected with the pTK::PRAREX2-luc reporter construct and stimulated with the indicated
concentrations of ATRA. After a total of 48 h from the beginning of transfection, luciferase activity of transfected cells stimulated with vehicle or ATRA was
determined by measurement of 'relative luciferase units' in a luminometer. Luciferase activity is expressed as x-fold induction (means ± s.e.m.) over basal
activity of vehicle-treated controls (n = 3; P < 0.05)
Statistical analysis
Statistics were performed by the unpaired, one-sided Student's
t-test. Differences were considered statistically different at the
P < 0.05 level. All data are shown as means ± s.e.m.
RESULTS
DSL-6A/C1 express duct cell-specific markers
To verify the ductal phenotype of DSL-6A/Cl cells, we initially
examined the expression of cell type-specific markers in two well-
characterized pancreatic carcinoma cell lines, AR42J and Dan-G,
and compared them with DSL-6A/Cl cells. We have previously
described the AR42J cell line as an amphicrine pancreatic carci-
noma cell line, which combines exocrine acinar with neuro-
endocrine features (Rosewicz et al, 1992b). The ductal phenotype of
Dan-G cells has previously been confirmed by cytokeratin pheno-
typing (Rosewicz et al, 1995a). Using a cDNA for the pancreatic
acinar cell-specific human amylase in Northern blot analysis, we
detected a single hybridization band with a molecular size of 1.8 kb
only in AR42J cells, but not in Dan-G or in DSL-6A/C1 cells
(Figure 1). Hybridization with a cDNA probe for the neuro-
endocrine vesicle membrane-specific protein synaptophysin reveals
a hybridization signal ofapproximately 2.8 kb only in AR42J cells,
but could not be detected in Dan-G or in DSL-6A/C1 cells (Figure
1). Using a human cDNA probe for carbonic anhydrase II (CAII),
which is specifically expressed in pancreatic duct cells, we obtained
a hybridization signal of about 2.0 kb both in Dan-G cells and in
DSL-6A/Cl cells, but not in AR42J cells (Figure 1). Therefore,
DSL-6A/Cl cells, although derived from a pancreatic acinar carci-
noma, fail to express pancreatic acinar and neuroendocrine markers,
but do express CAII - a marker gene specifically restricted to duct
cells ofthe pancreas (Kim et al, 1990).
Effects of all-trans-retinoic acid on cell growth and
transactivation of a RARE reporter construct in
DSL-6AIC1 cells
As an initial attempt to determine the responsiveness of a dediffer-
entiated pancreatic acinarcell line to the antiproliferative effects of
retinoids, we examined the effects of the naturally occurring
retinoid all-trans-retinoic acid (ATRA) on anchorage-dependent
growth in DSL-6A/C cells. We incubated DSL-6A/Cl cells with
ATRA over a period of 4 days and determined cell number every
24 h. For initial experiments, we chose 10 gM ATRA because this
represents the concentration which can be achieved after oral
uptake of this substance at maximal, non-toxic plasma levels in
humans (Muindi et al, 1992). After incubation with ATRA, we
observed a significant time-dependent growth inhibition in DSL-
6A/C1 cells as early as 2 days (74.9±7.4% of control, n = 3, P <
0.05; Figure 2). Furthermore, the antiproliferative effects ofATRA
are dose dependent, with half-maximal growth inhibition observed
at 100 nM ATRA (77.5±10.8% of control, n = 6, P < 0.05) and
maximal inhibition at 10 gM ATRA (55.7 ± 7.6% ofcontrol, n = 6,
P < 0,05; Figure 3A).
Having shown that DSL-6A/C cells are sensitive in terms of
ATRA-mediated growth inhibition, we next decided to evaluate
the transcriptional activation of retinoid-regulated genes in this
cell line to gain further evidence as to whether retinoid-regulated
gene transcription accounts for the antiproliferative effects of
ATRA. We therefore investigated the effects of ATRA on transac-
tivation of a retinoic acid responsive element linked to a luciferase
reporter gene. We transiently transfected DSL-6A/C1 cells with
the pTK::PRAREx2-luciferase reporter construct. Stimulation of
transient transfected DSL-6A/Cl cells with ATRA resulted in a
dose-dependent stimulation ofluciferase activity with a maximum
at 10 JIM ATRA (78.6±9.9% over control, n = 3, P < 0.05; Figure
3B). These data demonstrate that incubation of DSL-6A/Cl cells
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Figure 4 Dose-dependent effects of retinoid analogues on proliferation of
DSL-6A/C1 cells. Proliferation of DSL-6A/C1 cells was determined by cell
counts after incubation with the respective retinoid at the indicated
concentrations over 120 h. All data are expressed as per cent of vehicle-
treated control cells. Shown are the means (± s.e.m.) of three independent
experiments, each performed in triplicates *P < 0.05 vs control
with ATRA results in growth inhibition and transactivation at
comparable concentrations of ATRA, suggesting a tight correla-
tion between retinoid-regulated gene expression and the ATRA-
induced growth inhibition in DSL-6A/C 1 cells.
Effects of retinoid analogues on proliferation of
DSL-6A/C1 cells
We next asked which nuclear retinoid receptor family might be
responsible for the ATRA-mediated growth inhibition and tran-
scriptional control of retinoid responsive genes in DSL-6A/C1
cells. We therefore compared the effects ofthe retinoid analogues
ATRA, 13-cis- and 9-cis-RA on anchorage-dependent growth.
Figure 4 demonstrates the dose-dependent retinoid effects on
anchorage-dependent growth of DSL-6A/C1 cells. Maximal
antiproliferative effects could be observed with 10 ,M of each
retinoid analogue. The biological activity of these retinoids on an
equimolar basis (at 10 gM 120 h-') in DSL-6A/C1 is as follows:
ATRA > 13-cis-RA > 9-cis-RA. At lower concentrations (<1 gM),
only 13-cis-RA and ATRA exerted similar growth inhibitory
effects, whereas 9-cis-RA failed to demonstrate a significant
growth inhibition (Figure 4). Although isomerization and degrada-
tion have to be considered, these observations suggest that
retinoid-mediated growth inhibition in DSL-6A/C1 cells might be
due to activation of the RAR receptor family rather than the RXR
pathway.






Figure 5 Expression of nuclear retinoid receptors in DSL-6A/C1 cells (RT-
PCR analysis). Using receptor subtype specific oligonucleotide primers,
expression of retinoid receptors (RAR/RXR) in DSL-6A/C1 cells was
characterized by RT-PCR. Size determination as indicated on the left was
performed using a 100-bp DNA ladder (M). As a negative internal control,
one RNA aliquot was amplified without prior reverse transcription (-); the
respective complementary DNA for each receptor subtype (cDNA) served as
a positive control. Shown is a representative of 3-5 independent RT-PCR
reactions
was performed with the respective receptor cDNA yielding ampli-
fication products of the expected size for each receptor subtype
(Figure 5). The validity of the primers for rat tissues has previ-
ously been described (Rosewicz et al, 1995a).
To exclude amplification signals arising from contaminating
genomic DNA, each PCR was initially performed without prior
reverse transcriptase reaction and repeatedly found to be negative.
Using the receptor subtype-specific primers we detected expres-
sion of RAR-a, RAR-P and RXR-a, whereas no amplification
signal forRAR-y,RXR-P and RXR-ycould be detected (Figure 5).
Expression of nuclear retinoid receptors in DSL-6A/C1
cells
We next examined the expression pattern ofnuclear retinoid recep-
tors to gain more information about which retinoid receptor
subtype might mediate retinoid action in this cell line. To charac-
terize the RAR/RXR subtype expression pattern, we applied the
very sensitive RT-PCR analysis using receptor subtype-specific
primers because retinoid receptors are often expressed as low
abundance mRNAs, thereby barely detectable by standard
Northern blot analysis. As an internal positive control RT-PCR
Effects of RAR-specific agonists on proliferation of
DSL-6A/C1 cells
Data obtained from anchorage-dependent growth assays using
different retinoid analogues indicate that only retinoids, which
predominantly activate the RARs, result in significant growth inhi-
bition of DSL-6A/C1 cells at lower concentrations. We therefore
assumed that ATRA-mediated effects on growth and transactiva-
tion are mediated by a subtype of the RAR family expressed in
DSL-6A/C1 cells (RAR-a orRAR-P). We examined, therefore, the
effects of RAR subtype-specific retinoids on anchorage-dependent
growth of DSL-6A/Cl cells using the RAR-a subtype-specific
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Figure 6 Effects of RAR-specific agonists on growth in DSL-6AIC1 cells.
Cell growth of DSL-6A/C1 cells was determined by cell counts after
incubation with the RAR-a selective agonist Ro-40-6055, the RAR-,B
selective agonist Ro 48-2249 and ATRA. Cells were incubated with the
respective retinoid at the indicated concentrations over 96 h. Means
(± s.e.m.) of three independent experiments, each performed in triplicate, are
expressed as per cent of vehicle-treated control cells. *P < 0.05 vs control
retinoid Ro 40-6055 and the RAR-f-specific agonist Ro 48-2249.
Both agonists have been shown to bind and activate preferentially
the corresponding receptor subtype (Crettaz et al, 1990). The
antiproliferative effects of the RAR-a-specific agonist were
comparable to the growth-inhibitory effects of ATRA on an
equimolar basis: 00 nm Ro 40-6055 (RAR-a specific agonist)
77.0±3.1% of control (n = 3, P < 0.05; Figure 6) versus 100 nM
ATRA 76.2±3.3% ofcontrol (n = 3, P <0.05; Figure 6). In contrast,
the RAR-j-specific retinoid Ro 48-2249 was mainly ineffective.
Effects of the RAR-a-specific antagonist Ro 41-5253 on
ATRA-mediated growth inhibition and transactivation
To further substantiate the role of the RAR-a receptor subtype in
mediating the effects of ATRA in DSL-6AIC 1 cells, we used the
RAR-a-specific antagonist Ro 41-5253 in growth and transactiva-
tion assays. This retinoid has been shown to revert, selectively,
RAR-a-mediated retinoid effects (Apfel et al, 1992). Incubation of
DSL-6AICl cells with this antagonist at the maximal concentration
used in our experiments had no effect on growth (data not shown).
However, ATRA-mediated growth inhibition can be blocked by
the RAR-a-specific antagonist Ro 41-5253 in a dose-dependent
manner, with a complete growth inhibition observed at an antago-
nist concentration of 1-10 ,UM (Figure 7A). Similar effects could
also be observed when we investigated ATRA-mediated transacti-
vation of the pTK::4RAREx2-luc reporter construct in transiently
transfected DSL-6A/C 1 cells: incubation with 1O,M RAR-a-
specific antagonist Ro 41-5253 completely blocks the stimulation
ofluciferase activity induced by 100 nM ATRA (Figure 7 B).
DISCUSSION
Retinoids have been shown to exert profound effects on cellular
growth and differentiation in a variety of malignant cells in vitro
and in vivo (Lotan, 1980; Bollag, 1983; Lotan et al, 1990).
Moreover, retinoids have been proven clinically beneficial in
certain premalignant lesions (e.g. dysplasias of the cervix, the
Ro 41-5253 - 8 7 6 5 - 5 -log M
Figure 7 The RAR-a antagonist Ro 41-5253 blocks ATRA-mediated growth
inhibition and transactivation of the pTK::4RAREX2-luc reporter construct.
(A) Anchorage-dependent growth assay: DSL-6A/C1 cells were incubated
with the indicated concentrations of the RAR-a antagonist Ro 41-5253 and
100 nm ATRA over 96 h. Cell counts were determined and expressed as per
cent of vehicle-treated control cells. Shown are the means ± s.e.m. of three
independent experiments, each performed in triplicates. * P-values <0.05 vs
ATRA-mediated growth inhibition. (B) Transactivation assays: DSL-6A/C1
cells were transiently transfected with thepTK::PRAREX2-luc reporter
construct and stimulated with 100 nm ATRA with or without the presence of
the RAR-ax antagonist Ro 41-5253. Luciferase activity of transfected cells
(n = 3) was determined in a luminometer and expressed as x-fold induction
(means ± s.e.m.) over basal activity of vehicle treated controls; *P-values
< 0.05 vs ATRA-mediated induction of luciferase activity
respiratory tract, in the head and neck area) and in various malig-
nancies (for review see Bollag and Holdener, 1992). We have
previously shown that retinoids induce cellular differentiation and
inhibit proliferation of human ductal carcinoma cells in vitro and
in vivo (Rosewicz et al, 1995a). In addition, combination therapy
of retinoic acid with interferon a in patients with advanced, unre-
sectable carcinoma ofthe pancreas results in prolonged survival of
responsive patients (Brembeck et al, 1998). However, the molec-
ular basis of retinoid action in pancreatic carcinoma cells is still
incompletely understood, especially with regard to which retinoid
receptor subtype might account for the antiproliferative effects of
retinoids.
To further dissect this problem, we therefore decided to investi-
gate the molecular effects ofretinoids in the pancreatic carcinoma
cell line DSL-6A/C1, because this cell system provides the unique
features of a primary acinarpancreatic carcinoma which has dedif-
ferentiated into a ductal phenotype (Pettengill et al, 1993). Some
experimental evidence suggests that, at least in some rodents, this
sequence of malignant transformation might best reflect the in
vivo situation of pancreatic carcinogenesis (Dissin et al, 1975;
Longnecker and Curphey, 1975; Bockman et al, 1976, 1978;
Satake et al, 1984; Scarpelli et al, 1984; De Lisle and Logsdon,
1990; Longnecker et al, 1992).
The ductal phenotype of DSL-6A/C1 cells was confirmed by
characterizing the expression pattern of pancreatic cell type-
specific marker genes compared with two other well-defined
pancreatic carcinoma cell lines, Dan-G and AR42J. Dan-G cells
represent a retinoid-sensitive, human ductal pancreatic carcinoma
cell line (Rosewicz et al, 1995a). AR42J cells were established
from an azaserine-treated rat model and represent a retinoid-insen-
sitive, acinar pancreatic carcinoma cell line with neuroendocrine
features (Rosewicz et al, 1992b, 1995a). By Northern blot
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analysis. we demonstrated expression of the acinar cell marker
amylase and the neuroendocrine marker gene synaptophysin.
whereas the ductal cell marker carbonic anhydrase II (CAll) is not
expressed in the amphicrine cell line AR42J. In contrast. DSL-
6A/CI cells (despite their origin from an azaserine-induced acinar
pancreatic carcinoma) have lost the expression of the acinar
marker amylase. but express the duct cell-specific marker CAII.
Expression of synaptophysin in these cells could not be detected.
indicating a lack oftransdifferentiation to a neuroendocrine pheno-
type. These results are in good agreement with the study of
Pettengill et al (1993) regarding the histopathological features and
the expression pattern of cytokeratins. indicating that DSL-6A/C1
cells represent a pancreatic carcinoma cell line with a bona fide
ductal phenotype.
Having confirmed the ductal phenotype of DSL-6A/C1 cells.
we next investigated whether these cells are retinoid sensitive in
terms of growth inhibition. Using an anchorage-dependent growth
assay. we observed that treatment with ATRA results in a time- and
dose-dependent growth inhibition. Compared with 13-cis-RA and
9-cis-RA. ATRA was the most potent antiproliferative retinoid.
Somewhat less pronounced growth inhibitory effects were
observed for the stereoisomer of ATRA. 13-cis-RA. whereas the
retinoid analogue 9-cis-RA failed to inhibit cell growth at lower.
therapeutically relevant concentrations (<100 nrm). These results
indicate that retinoid-mediated growth inhibition is mainly due to
activation of the RAR receptor family because ATRA predomi-
nantly activates the RAR subtypes (Heyman et al. 1992: Leid et al.
1992a. 1992b: Giguere. 1994).
We next focused on the molecular basis of ATRA-mediated
effects in DSL-6A/CI cells and tested the ability of ATRA to stim-
ulate gene transcription of a synthetic RARE reporter construct.
In transient transfection assays with the pTK::PRAREx2-luc
construct. we demonstrated that ATRA dose-dependently mediates
transactivation ofthis reporter construct. The dose-response curve
of ATRA-mediated transactivation correlates tightly with the
growth inhibitory effects observed in the anchorage-dependent
growth assays. These data are compatible with the hypothesis that
antiproliferative effects ofretinoids are mediated by the transcrip-
tional control of genes regulating cellular growth. However. it
should be kept in mind that the effects of retinoids might also be
mediated by transcriptional repression as well as functional inter-
ference with the transcription factor AP-1 (Giguere. 1994).
To achieve further insight into the molecular mechanism of
retinoid action in this cell system. we characterized the expression
of the RAR and RXR subtypes. To our surprise. we found a very
restrictedexpression pattern ofRAR/RXR subtypes in DSL-6A/CI
cells. Using the highly sensitive RT-PCR technique. we detected
two RAR subtypes (RAR-a and RAR-() and only one member of
the RXR family (RXR-a). RAR-y. RXR-0 and RXR-y are not
expressed in these cells. The lack of RXR-y expression is not
surprising because this subtype exhibits a very restricted expression
pattern in only a few tissues (Dolle et al. 1990). and is also not
expressed in a broad panel of human pancreatic carcinoma cell
lines (Rosewicz et al. 1995a). In contrast to the DSL-6A/C1 cells.
all previously characterized human ductal pancreatic carcinoma
cell lines express the RAR-yas well as the RXR-, (Rosewicz et al.
1995a). The retinoid-insensitive rat amphicrine carcinoma cell line
AR42J shows, similar to the retinoid-sensitive DSL-6A/C1 cells.
no expression of the RAR-y. The selective loss of the RAR-y
subtype might be due to the malignant transformation of acinar
cells because this receptor subtype is expressed in normal pancre-
atic acinar cells (Xu et al. 1996).
Each receptor subtype might fulfill a distinct biological function
in a given cell by activating a panel of responsive genes (Giguere.
1994). We therefore investigated which receptor subtype might be
responsible for ATRA-mediated growth inhibition in DSL-6AIC1
cells. Because ATRA predominantly activates the RAR subtypes
and DSL-6AIC1 cells only express RAR-a and RAR-0. we inves-
tigated the effects of two RAR subtype-specific retinoids on
anchorage-dependent growth: Ro 40-6055, a specific agonist of
the RAR-a subtype: and Ro 48-2249. a RAR-P specific agonist
(Crettaz et al. 1990). Only the RAR-a specific agonist exerted
dose-dependent antiproliferative effects similar to equimolar
concentrations of ATRA. whereas the RAR-(-specific retinoid Ro
48-2249 had no antiproliferative effects at concentrations less than
I gm. This suggests an important role for the RAR-a subtype in
mediating the effects of ATRA in DSL-6A/C1 cells.
If the RAR-a subtype is responsible for growth inhibition and
transactivation of the RARE reporter construct in DSL-6A/C1
cells, it should be possible to block the ATRA-mediated effects by
antagonizing the RAR-a subtype. To test this hypothesis. we used
the highly specific RAR-a antagonist Ro 41-5253 (Apfel et al.
1992) in anchorage-dependent growth and transactivation assays.
ATRA-mediated growth inhibition as well as transactivation of the
RARE reporter construct could be completely blocked by the
RAR-a antagonist. suggesting that RAR-a is crucial for mediating
the biological effects of ATRA in DSL-6AC1 cells.
Recent studies indicated that the expression pattem of distinct
retinoid receptor subtypes determines retinoid-mediated effects in
a given tissue (Giguere. 1994). Forexample. RAR-a is found to be
responsible for growth inhibition in breast cancer cells (van der
Leede et al. 1995). whereas RAR-1 mediates antiproliferative
effects in fibroblasts (Lee et al. 1992) and RAR-yis predominantly
responsible for growth inhibition by retinoids in human teratocar-
cinoma (Moasser et al. 1994) or neuroblastoma (Marshall et al.
1995). Despite this divergence in different tissues. the identifica-
tion of a distinct receptor subtype mediating the antiproliferative
effects of retinoids in a given cell type provides a powerful thera-
peutic tool to potentiate the antiproliferative effects and minimize
side-effects potentially mediated by other receptor subtypes.
Based on the different retinoid receptor expression pattern
between rat and human pancreatic carcinoma cells. the implica-
tions of this study for experimental therapy of human pancreatic
cancer have to be interpreted cautiously. However. the results of
the present study are indicative that receptor subtype-specific
retinoids (i.e. RAR-a-specific agonists) might be an attractive
alternative to all-trans-retinoic acid in the experimental treatment
ofpancreatic carcinoma.
In summary, we have demonstrated that the antiproliferative
effects of retinoids in the ductal pancreatic carcinoma cell line
DSL-6A/CI are predominantly mediated by the RAR-a subtype.
Moreover. DSL-6A/C1 cells as a model ofductal adenocarcinoma
derived from dedifferentiated pancreatic acinar cells provide a
feasible in vitro system to study the molecular mechanisms under-
lying growth inhibitory effects of retinoids in ductal pancreatic
carcinoma cells.
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